Drug Trial Radar · NCT04814108
A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma
Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
92
Actual
Start
Jul 28, 2021
Primary completion
Oct 22, 2025
Study completion Oct 22, 2025
Sponsor
- Lead sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Mar 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).
Conditions
- Uterine Serous Carcinoma
Interventions
AzenosertibDrug
Azenosertib is an investigational drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and severity of TEAEsTime frame: 2 years
- Objective Response Rate as defined by the revised RECIST v1.1 as assessed by ICRTime frame: 2 years
Locations
56 sites in 4 countries. Site status is shown where the registry gives one.
Alaska Women's Cancer Care
Anchorage, Alaska
Honor Health
Phoenix, Arizona
Arizona Oncology Associates Wilmot HOPE
Tucson, Arizona
Banner University Medical Center Tucson
Tucson, Arizona
University of California Irvine Medical Center
Orange, California
University of California San Francisco at Mission Bay
San Francisco, California
Mount Sinai Medical Center
Miami Beach, Florida
Sarasota Memorial Hospital
Sarasota, Florida
University of South Florida
Tampa, Florida
Northside Hospital
Atlanta, Georgia
Georgia Cancer Center at Augusta University
Augusta, Georgia
Northwestern University
Evanston, Illinois
Maryland Oncology Hematology
Annapolis, Maryland
University of Maryland Medical Center
Baltimore, Maryland
Oakland Medical Group
Detroit, Michigan
Corewell Health
Grand Rapids, Michigan
Revive Clinical Research
Sterling, Michigan
HCA Midwest Health Kansas City Research
Kansas City, Missouri
Center of Hope
Reno, Nevada
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Optimum Clinical Research Group- Women's Oncology
Albuquerque, New Mexico
Westchester Medical Center
Hawthorne, New York
University of Cincinnati
Cincinnati, Ohio
Oncology Hematology Care
Cincinnati, Ohio
Trihealth Cancer Institute
Cincinnati, Ohio
Ohio State University James Cancer Hospital
Columbus, Ohio
University of Oklahoma Peggy and Charles Stephenson Cancer Center
Oklahoma City, Oklahoma
Willamette Valley Cancer Institute
Eugene, Oregon
Providence Portland Medical Center
Portland, Oregon
Northwest Cancer Specialists
Portland, Oregon
Temple University Hospital
Philadelphia, Pennsylvania
Ascension St. Thomas Midtown Hospital
Nashville, Tennessee
Texas Oncology Austin
Austin, Texas
Texas Oncology Fort Worth Cancer Center
Fort Worth, Texas
MD Anderson Cancer Center
Houston, Texas
Texas Oncology Gulf Coast
Houston, Texas
Texas Oncology San Antonio
San Antonio, Texas
University of Virginia Cancer Center
Charlottesville, Virginia
VCU Health System
Richmond, Virginia
Virginia Cancer Specialists
Warrenton, Virginia
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.